• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Feb 2002; 61(2): 121–127.
PMCID: PMC1753997

Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis

Abstract

Background: Antibodies targeting DNA topoisomerase I (ATA) or centromere proteins (ACA) are associated with clinical subsets of patients with systemic sclerosis (SSc). The occurrence of those autoantibodies is considered to be mutually exclusive.

Objective: To describe the clinical and immunogenetic data of three patients who are co-expressing both antibodies, and then review previous publications.

Methods: Both antibodies were detected by different methods, including indirect immunofluorescence technique, enzyme linked immunosorbent assay, immunodiffusion, and immunoblot. Patients were HLA typed by serological and molecular genetic methods. Data were extracted from published reports for comparison. The search for published studies was through Medline and other database research programmes.

Results: During routine laboratory diagnostics over several years three patients with scleroderma and coincidence of ATA and ACA were identified: patient 1 with diffuse SSc, Raynaud's phenomenon, puffy fingers and fingertip necrosis, contractures, and calcinosis; patient 2 with diffuse SSc, Raynaud's phenomenon, oedema of the hands, and interstitial calcinosis of hands, knees, and shoulders, and pulmonary fibrosis; patient 3 with scleroderma of hands, forearms, and face, Raynaud's phenomenon, puffy fingers, finger contractures, fingertip necrosis, and calcinosis. All three patients studied were carriers of HLA alleles known to be associated with these autoantibodies. In serial measurements the concentrations of the two antibodies showed independent or even reverse fluctuations. Screening of 100 patients with ACA for ATA and vice versa disclosed no further patients with coincidence of these antibodies. Twenty eight cases of ACA/ATA coexistence in 5423 patients (0.52%) with SSc or SSc associated symptoms were found in an analysis of published studies.

Conclusion: The expression of ATA and ACA is not totally mutually exclusive, but coincidence is rare (<1% of patients with SSc). Patients with both autoantibodies often have diffuse scleroderma and show immunogenetic features of both antibody defined subsets of SSc.

Full Text

The Full Text of this article is available as a PDF (147K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed]
  • Steen VD, Powell DL, Medsger TA., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. [PubMed]
  • Vázquez-Abad D, Rothfield NF. Autoantibodies in systemic sclerosis. Int Rev Immunol. 1995;12(2-4):145–157. [PubMed]
  • Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93–151. [PubMed]
  • Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 1996 Nov;22(4):709–735. [PubMed]
  • Catoggio LJ, Skinner RP, Maddison PJ. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population. Rheumatol Int. 1983;3(1):19–21. [PubMed]
  • Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol. 1994 Jul;19(4):298–302. [PubMed]
  • Kallenberg CG, Pastoor GW, Wouda AA, The TH. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982 Aug;41(4):382–387. [PMC free article] [PubMed]
  • Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol. 1995 Jul-Aug;10(4):438–445. [PubMed]
  • Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol. 2000 Jun;27(6):1403–1407. [PubMed]
  • Zuber M, Gotzen R, Filler I. Clinical correlation of anticentromere antibodies. Clin Rheumatol. 1994 Sep;13(3):427–432. [PubMed]
  • Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997 Sep;103(3):242–248. [PubMed]
  • Riboldi P, Asero R, Origgi L, Crespi S, Meroni PL, Sguotti C, Sabbadini MG. Antinuclear antibodies in progressive systemic sclerosis. Clin Exp Rheumatol. 1985 Jul-Sep;3(3):205–211. [PubMed]
  • Jabłońska S, Błaszczyk M, Jarzabek-Chorzelska M, Chorzelski T, Kołacińska-Strasz Z. Immunological markers of the subsets of systemic scleroderma and its overlap. Arch Immunol Ther Exp (Warsz) 1991;39(4):381–390. [PubMed]
  • Genth E, Mierau R, Genetzky P, von Mühlen CA, Kaufmann S, von Wilmowsky H, Meurer M, Krieg T, Pollmann HJ, Hartl PW. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 1990 May;33(5):657–665. [PubMed]
  • Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, Arnett FC. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest. 1992 Apr;89(4):1208–1213. [PMC free article] [PubMed]
  • Reveille JD, Durban E, MacLeod-St Clair MJ, Goldstein R, Moreda R, Altman RD, Arnett FC. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest. 1992 Sep;90(3):973–980. [PMC free article] [PubMed]
  • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. [PubMed]
  • Dick T, Mierau R, Sternfeld R, Weiner EM, Genth E. Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). J Rheumatol. 1995 Jan;22(1):67–72. [PubMed]
  • von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323–358. [PubMed]
  • Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum. 1994 Mar;37(3):391–394. [PubMed]
  • Hirakata M, Akizuki M, Miyachi K, Matsushima H, Okano T, Homma M. Coexistence of CREST syndrome and primary biliary cirrhosis. Serological studies of two cases. J Rheumatol. 1988 Jul;15(7):1166–1170. [PubMed]
  • Speranskii AI, Riazantseva TA, Guseva NG, Melkumova KL, Ivanova SM. Antikardiolipinovye antitela i drugie immunologicheskie narusheniia u bol'nykh sistemnoi sklerodermiei. Revmatologiia (Mosk) 1990 Jul-Sep;(3):11–14. [PubMed]
  • Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 1999 Mar;12(2):137–142. [PubMed]
  • Poormoghim H, Lucas M, Fertig N, Medsger TA., Jr Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000 Feb;43(2):444–451. [PubMed]
  • Okano Y, Steen VD, Medsger TA., Jr Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1993 Nov 15;119(10):1005–1013. [PubMed]
  • Pollard KM, Reimer G, Tan EM. Autoantibodies in scleroderma. Clin Exp Rheumatol. 1989 Sep-Oct;7 (Suppl 3):S57–S62. [PubMed]
  • Jarzabek-Chorzelska M, Błaszczyk M, Kołacińska-Strasz Z, Jabłonska S, Chorzelski T, Maul GG. Are ACA and Scl 70 antibodies mutually exclusive? Br J Dermatol. 1990 Feb;122(2):201–208. [PubMed]
  • Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol. 1999 Aug;117(2):207–208. [PMC free article] [PubMed]
  • Behr J, König G, Meurer M, Krieg T. Pulmonale Manifestation bei progressiver, systemischer Sklerodermie: Prognostische Wertigkeit der Zentromerantikörper und Antikörper gegen Scl-70 Nukleoprotein. Pneumologie. 1990 Jun;44(6):822–825. [PubMed]
  • Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998 Jan;37(1):15–20. [PubMed]
  • Cassani F, Tosti A, Bianchi FB, Fusconi M, Selleri L, Baffoni L, Veronesi S, Volta U, Lenzi M, Pisi E. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies. Clin Exp Rheumatol. 1987 Jan-Mar;5(1):23–28. [PubMed]
  • Chang M, Wang RJ, Yangco DT, Sharp GC, Komatireddy GR, Hoffman RW. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol. 1998 Oct;89(1):71–78. [PubMed]
  • Conrad K, Stahnke G, Liedvogel B, Mehlhorn J, Barth J, Blasum C, Altmeyer P, Sönnichsen N, Frank KH. Anti-CENP-B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemic sclerosis (scleroderma). J Rheumatol. 1995 Jul;22(7):1286–1294. [PubMed]
  • de Rooij DJ, van de Putte LB, Habets WJ, Verbeek AL, van Venrooij WJ. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases. Scand J Rheumatol. 1988;17(5):353–364. [PubMed]
  • de Rooij DJ, Van de Putte LB, Habets WJ, Van Venrooij WJ. Marker antibodies in scleroderma and polymyositis: clinical associations. Clin Rheumatol. 1989 Jun;8(2):231–237. [PubMed]
  • Falkner D, Wilson J, Medsger TA, Jr, Morel PA. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum. 1998 Jan;41(1):74–80. [PubMed]
  • Falkner D, Wilson J, Fertig N, Clawson K, Medsger TA, Jr, Morel PA. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol. 2000 May;27(5):1196–1202. [PubMed]
  • Fanning GC, Welsh KI, Bunn C, Du Bois R, Black CM. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol. 1998 Feb;37(2):201–207. [PubMed]
  • Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G, Neri R, Bombardieri S. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol. 1991 Dec;18(12):1826–1832. [PubMed]
  • Gabay C, Kahn MF. Les sclérodermies masculines: rôle de l'exposition professionnelle. Schweiz Med Wochenschr. 1992 Nov 14;122(46):1746–1752. [PubMed]
  • Grigolo B, Mazzetti I, Meliconi R, Bazzi S, Scorza R, Candela M, Gabrielli A, Facchini A. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol. 2000 Sep;121(3):539–543. [PMC free article] [PubMed]
  • Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol. 1999 Aug;117(2):395–402. [PMC free article] [PubMed]
  • Herrmann K, Schulze E, Heckmann M, Schubert I, Meurer M, Ziegler V, Haustein UF, Mehlhorn J, Krieg T. Type III collagen aminopropeptide and laminin P1 levels in serum of patients with silicosis-associated and idiopathic systemic scleroderma. Br J Dermatol. 1990 Jul;123(1):1–7. [PubMed]
  • Haustein UF, Ziegler V, Herrmann K, Mehlhorn J, Schmidt C. Silica-induced scleroderma. J Am Acad Dermatol. 1990 Mar;22(3):444–448. [PubMed]
  • Hietarinta M, Tertti R, Lassila O. A patient with systemic sclerosis, severe cytopenias and the simultaneous presence of anti-centromere and anti-SCL-70-antibodies. Clin Exp Rheumatol. 1993 Jul-Aug;11(4):457–458. [PubMed]
  • Hietarinta M, Lassila O, Hietaharju A. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol. 1994;23(2):64–67. [PubMed]
  • Igarashi A, Takehara K, Soma Y, Kikuchi K, Ishibashi Y. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis. Dermatologica. 1990;180(3):136–140. [PubMed]
  • Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Høier-Madsen M, Wiik A, Petersen J. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol. 1998 Jan;37(1):39–45. [PubMed]
  • Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody--a specific marker of systemic sclerosis. Br J Dermatol. 1986 Oct;115(4):393–401. [PubMed]
  • Jarzabek-Chorzelska M, Blaszczyk M, Kolacinska-Strasz Z, Chorzelski T, Jabłońska S, Maul GG. Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion. Arch Dermatol Res. 1990;282(2):76–83. [PubMed]
  • Johanet C, Agostini MM, Vayssairat M, Abuaf N. Autoanticorps anti-Scl-70 et anti-centromère. Marqueurs biologiques de 2 variétés différentes de sclérodermie systémique. Presse Med. 1989 Feb 11;18(5):207–211. [PubMed]
  • Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988 Aug;47(8):634–641. [PMC free article] [PubMed]
  • Kipnis RJ, Craft J, Hardin JA. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum. 1990 Sep;33(9):1431–1437. [PubMed]
  • Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA, Jr, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum. 1999 Mar;42(3):465–474. [PubMed]
  • Lakomek HJ, Guldner HH, Bautz FA, Goerz G, Kind P, Mensing H, Krüskemper HL. Kernantikörper als serologische Marker der progressiv systemischen Sklerodermie (PSS). Hautarzt. 1987 Feb;38(2):63–69. [PubMed]
  • Maekawa S, Yano E, Shintani S. [A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies]. Ryumachi. 1992 Oct;32(5):515–521. [PubMed]
  • McCarty GA, Rice JR, Bembe ML, Barada FA., Jr Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum. 1983 Jan;26(1):1–7. [PubMed]
  • McHugh NJ, Whyte J, Artlett C, Briggs DC, Stephens CO, Olsen NJ, Gusseva NG, Maddison PJ, Black CM, Welsh K. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol. 1994 May;96(2):267–274. [PMC free article] [PubMed]
  • McNeilage LJ, Whittingham S, McHugh N, Barnett AJ. A highly conserved 72,000 dalton centromeric antigen reactive with autoantibodies from patients with progressive systemic sclerosis. J Immunol. 1986 Oct 15;137(8):2541–2547. [PubMed]
  • McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum. 1989 Jan;32(1):54–60. [PubMed]
  • Meurer M, Scharf A, Luderschmidt C, Braun-Falco O. Zentromerantikörper und Antikörper gegen Scl-70-Nucleoprotein bei progressiver systemischer Sklerodermie.Diagnostische und prognostische Bedeutung. Dtsch Med Wochenschr. 1985 Jan 4;110(1):8–14. [PubMed]
  • Parodi A, Puiatti P, Rebora A. Serological profiles as prognostic clues for progressive systemic scleroderma: the Italian experience. Dermatologica. 1991;183(1):15–20. [PubMed]
  • Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G. Clinical setting of patients with systemic sclerosis by serum autoantibodies. Clin Rheumatol. 1997 Jun;16(4):378–383. [PubMed]
  • Renier G, Le Normand I, Chevailler A, Verret JL, Renier JC, Hurez D. Anticorps anti-centromères. Etude de 67 sérums positifs. Rev Med Interne. 1992 Nov;13(6):413–418. [PubMed]
  • Ruffatti A, Calligaro A, Ferri C, Bombardieri S, Gambari PF, Todesco S. Association of anti-centromere and anti-Scl 70 antibodies in scleroderma. Report of two cases. J Clin Lab Immunol. 1985 Apr;16(4):227–229. [PubMed]
  • Russo K, Hoch S, Dima C, Varga J, Teodorescu M. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. J Rheumatol. 2000 Jan;27(1):142–148. [PubMed]
  • Sato S, Ihn H, Soma Y, Shimozuma M, Shishiba T, Takehara K. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies. J Rheumatol. 1993 Nov;20(11):1961–1963. [PubMed]
  • Sato S, Takehara K. Hydrochloric acid treatment of HEp-2 cells for the detection of masked anticentromere antibody (ACA) Br J Dermatol. 1991 Aug;125(2):191–192. [PubMed]
  • Stahnke G, Meier E, Scanarini M, Northemann W. Eukaryotic expression of recombinant human centromere autoantigen and its use in a novel ELISA for diagnosis of CREST syndrome. J Autoimmun. 1994 Feb;7(1):107–118. [PubMed]
  • Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980 Jun;23(6):617–625. [PubMed]
  • van Venrooij WJ, Stapel SO, Houben H, Habets WJ, Kallenberg CG, Penner E, van de Putte LB. Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest. 1985 Mar;75(3):1053–1060. [PMC free article] [PubMed]
  • Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol. 1993 Apr;32(4):297–301. [PubMed]
  • Wade JP, Sack B, Schur PH. Anticentromere antibodies--clinical correlates. J Rheumatol. 1988 Dec;15(12):1759–1763. [PubMed]
  • Weiner ES, Earnshaw WC, Senécal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum. 1988 Mar;31(3):378–385. [PubMed]

Figures and Tables

Figure 1
Time courses of autoantibody concentrations. Serial measurements for the three patients. Fresh sera or samples from our serum bank (after storage at -30°C) were tested by ELISA, as outlined in "Patients and methods", for ATA (triangles) and anti-CENP-B ...
Figure 2
Radiograph of the right hand of patient No 2, eight years after disease onset.
Figure 3
Clinical characteristics of patients with ACA and ATA. Clinical data of 173 patients with ACA (tested with IIFT) and 118 patients with ATA (tested with immunodiffusion) were compared by chart review. Significant differences (p<0.05, Fisher's ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...